Tag: BOT

Botanix Pharmaceuticals CBD cannabidiol destroys skin superbug infections BTX 1801

Botanix’s CBD-based product destroys superbug skin infections in another ‘world first’

In another “world first” this week, Botanix Pharmaceuticals (ASX: BOT) has revealed its antimicrobial cannabidiol (CBD)-based product BTX 1801 can treat serious skin infections...
Botanix Pharmaceuticals ASX BOT clinical study cannabinoid CBD anti-inflammatory immunomodulation effects skin disease plaque psoriasis

Botanix study finds CBD has anti-inflammatory and immune modulating effects on skin disease

New results from a “world-first” study by Botanix Pharmaceuticals (ASX: BOT) has identified significant anti-inflammatory and immune modulating effects from using cannabidiol (CBD) to...
Botanix Pharmaceuticals ASX BOT University of Queensland cannabidiol treatment superbugs

Botanix Pharmaceuticals and University of Queensland to develop cannabidiol treatment for superbugs

Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) is moving ahead with developing its BTX 1801 pipeline product, a cannabidiol-based treatment for various dermatological conditions. BTX 1801 is...
Botanix Pharmaceuticals ASX BOT funded complete atopic dermatitis trial

Botanix Pharmaceuticals fully funded to complete phase 2 atopic dermatitis trial

Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) has raised A$8 million through an oversubscribed placement to professional, institutional and sophisticated investors across Australia and Asia. The raising...
Botanix Pharmaceuticals ASX BOT BTX 1204 phase 1b trial results

Botanix Pharmaceuticals receives strong results amid growing dermatitis rates

Dermatology company Botanix Pharmaceuticals (ASX: BOT) has published successful results from its phase 1b patient study looking into the safety profile of its cannabidiol-based...
Botanix Pharmaceuticals ASX BOT FDA acne study

Botanix receives FDA go-ahead for progressive acne treatment

Dermatology company Botanix Pharmaceuticals (ASX: BOT) has received the green light from the US Food and Drug Administration (FDA) for its BTX 1503 phase...
Botanix Pharmaceuticals ASX BOT cannabis atopic dermatitis treatment study enrolment

Botanix poised to kick-off new study with CBD-based atopic dermatitis treatment

Botanix Pharmaceuticals (ASX: BOT) has now enrolled all patients required to kick-off its phase 1b atopic dermatitis study where it will test is cannabidiol-based...
Botanix Pharma ASX BOT acne treatment outperforms current topical products study BTX 1503

Botanix’s acne treatment outperforms current ‘leading’ topical products

Botanix Pharmaceuticals’ (ASX: BOT) synthetic cannabidiol-based BTX 1503 acne treatment has performed better than “leading” topically applied acne products in reducing acne lesions during...
Botanix Pharma ASX BOT acne product antibiotic resistant acne cannabidiol

Botanix Pharma’s acne product effects antibiotic-resistant acne

Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) revealed trials of its synthetic cannabidiol-based acne product BTX 1503 has demonstrated antibacterial activity against acne. In the...
Botanix Pharmaceuticals ASX BOT dermatitis clinical trial phase 1b patients enrol

First patients enrolled for Botanix Pharmaceuticals’ dermatitis trial

Botanix Pharmaceuticals (ASX: BOT) has enrolled its first patients for its phase 1b clinical trial into its proprietary BTX 1204 treatment on atopic dermatitis sufferers. Atopic...
Botanix Pharmaceuticals ASX dermatitis BTX 1204

Botanix Pharmaceuticals kicks-off atopic dermatitis trials

Botanix Pharmaceuticals (ASX: BOT) is full steam ahead with beginning its atopic dermatitis study in Australia after getting the green light from the Human...